IQVIA downgraded by HSBC Securities with a new price target
$IQV
Biotechnology: Commercial Physical & Biological Resarch
Health Care
HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/25/2025 | $160.00 | Buy → Hold | HSBC Securities |
| 4/10/2025 | $170.00 | Overweight → Equal Weight | Barclays |
| 2/3/2025 | Buy → Neutral | BTIG Research | |
| 12/20/2024 | $250.00 | Overweight | Stephens |
| 10/14/2024 | Buy | Redburn Atlantic | |
| 9/4/2024 | $275.00 | Outperform | RBC Capital Mkts |
| 7/24/2024 | $266.00 → $242.00 | Buy → Hold | Jefferies |
| 6/6/2024 | $270.00 | Buy | Goldman |
HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00
Barclays downgraded IQVIA from Overweight to Equal Weight and set a new price target of $170.00
BTIG Research downgraded IQVIA from Buy to Neutral
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
SCHEDULE 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 17, 2025 /PRNewswire/ -- Venture Capital continues to flow in bunches into the AI in healthcare sector, with AI companies capturing more than half of digital health funding in Q1. Investors are seeking novel opportunities that tap into this space, with private companies such as Ellipsis Health and Autonomize AI recently receiving $45M and $28M respectively for their innovations. For other investors seeking opportunities among publicly traded companies, there's been plenty of development to follow from innovators, including from Avant Technologies, Inc. (OTCQB:AVAI), IQVIA Holdings Inc. (NYSE:IQV), S
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the "Best Mobile App for Patient Engagement" in the ninth-annual MedTech Breakthrough Awards program. IQVIA's breakthrough Health Research Space platform allows direct-to-patient data collection and engagement with patient-facing mobile apps that helps patients and their caregivers participate in decentralized clinical trials around the world. The platform is configurable, multilingual and compatible with web, iOS and Android and is available across many geographic regions, increasing p
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA's new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI and deep domain expertise are transforming business processes and patient outcomes. "This is a pivotal opportunity to deliver the precise, efficient workflows and insights required by the modern life sciences industry backed by deep industry expertise and powerful technology partnersh
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)